Mumbai, May 6 -- Zydus Lifesciences announced that the USFDA conducted GMP surveillance Inspection for the company's Unit 9 facility located at Zydus Biotech Park, Changodar, Ahmedabad. The inspection was conducted from 27 April to 5 May 2026.

The inspection closed with seven observations. There were no data integrity related observations. The company will closely work with the USFDA to address the observations expeditiously.

Published by HT Digital Content Services with permission from Capital Market....